GlassScriptPhysician profile
Casey J Henich
NPI 1003041740
$3,046.26
in general payments reported to CMS, 2019-2025
41 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,060 · 2020: $217 · 2021: $43.79 · 2022: $371 · 2023: $515 · 2024: $420 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $314.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $299.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.83 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $275.63 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $210.95 | 2019-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Abbvie INC. | $178.39 | 2021-2025 | |
| Pfizer INC. | $169.64 | 2019-2025 | |
| Amgen INC. | $149.42 | 2019-2025 | Otezla, Repatha, Repatha |
| Lucid Diagnostics INC. | $112.87 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $104.60 | 2019-2024 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $97.20 | 2019-2024 | Spravato, Xarelto |
| Sanofi-Aventis U.S. LLC | $81.56 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $77.79 | 2022-2023 | Quviviq |
| Gilead Sciences, INC. | $54.54 | 2019-2020 | |
| Edwards Lifesciences Corporation | $42.29 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Henich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.